CSTL / Castle Biosciences, Inc. (CSTL) Q4 2022 Earnings Call Transcript

Although the revenue and EPS for Castle Biosciences, Inc. (CSTL) give a sense of how its business performed in the quarter ended September 2023, it mi more_horizontal

Castle reported stronger Q2 revenue growth and a lower net loss than analysts anticipated. The company also raised its full-year revenue outlook. more_horizontal

While the top- and bottom-line numbers for Castle Biosciences, Inc. (CSTL) give a sense of how the business performed in the quarter ended June 2023, more_horizontal

Castle's CEO and board chairman each unloaded significant amounts of company stock. The company focuses on medical diagnostic tests, primarily to info more_horizontal

Castle Biosciences, Inc shares surged 55% to $20.64 on Friday after Novitas, a regional Medicare administrative contractor, reversed its draft policy more_horizontal

Novitas is withdrawing a draft policy that would have denied coverage for Castle's cancer tests. It must still wait on a new draft policy from the reg more_horizontal

A Medicare contractor proposed non-coverage of one of Castle's skin cancer tests. The company reiterated guidance. more_horizontal

Castle Biosciences' shares are down more than 3% this year. The company specializes in medical diagnostics to improve patient treatment plans. more_horizontal